AstraZeneca PLC (AZN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AstraZeneca PLC (AZN) has a cash flow conversion efficiency ratio of 0.048x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX2.34 Billion ≈ $284.95K USD) by net assets (GBX48.72 Billion ≈ $5.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AstraZeneca PLC - Cash Flow Conversion Efficiency Trend (1990–2025)
This chart illustrates how AstraZeneca PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AZN current and long-term liabilities for a breakdown of total debt and financial obligations.
AstraZeneca PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AstraZeneca PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Test Research Inc
TW:3030
|
0.085x |
|
Wanbangde Pharmaceutical Holding Group Co Ltd
SHE:002082
|
0.000x |
|
Jiayou International Logistics Co Ltd
SHG:603871
|
0.178x |
|
JTC PLC LS-01
F:2N9
|
N/A |
|
REN - Redes Energéticas Nacionais SGPS S.A
LS:RENE
|
-0.087x |
|
Wankai New Materials Co. Ltd.
SHE:301216
|
N/A |
|
Fibra Danhos
MX:DANHOS13
|
0.022x |
|
Cetc Potevio Science&Technology Co Ltd
SHE:002544
|
-0.016x |
Annual Cash Flow Conversion Efficiency for AstraZeneca PLC (1990–2025)
The table below shows the annual cash flow conversion efficiency of AstraZeneca PLC from 1990 to 2025. For the full company profile with market capitalisation and key ratios, see AZN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX48.72 Billion ≈ $5.93 Million |
GBX14.57 Billion ≈ $1.77 Million |
0.299x | +3.09% |
| 2024-12-31 | GBX40.87 Billion ≈ $4.97 Million |
GBX11.86 Billion ≈ $1.44 Million |
0.290x | +9.87% |
| 2023-12-31 | GBX39.17 Billion ≈ $4.77 Million |
GBX10.35 Billion ≈ $1.26 Million |
0.264x | -0.20% |
| 2022-12-31 | GBX37.06 Billion ≈ $4.51 Million |
GBX9.81 Billion ≈ $1.19 Million |
0.265x | +74.37% |
| 2021-12-31 | GBX39.29 Billion ≈ $4.78 Million |
GBX5.96 Billion ≈ $725.52K |
0.152x | -50.54% |
| 2020-12-31 | GBX15.64 Billion ≈ $1.90 Million |
GBX4.80 Billion ≈ $583.90K |
0.307x | +50.87% |
| 2019-12-31 | GBX14.60 Billion ≈ $1.78 Million |
GBX2.97 Billion ≈ $361.24K |
0.203x | +9.12% |
| 2018-12-31 | GBX14.04 Billion ≈ $1.71 Million |
GBX2.62 Billion ≈ $318.53K |
0.186x | -13.30% |
| 2017-12-31 | GBX16.64 Billion ≈ $2.02 Million |
GBX3.58 Billion ≈ $435.34K |
0.215x | -13.54% |
| 2016-12-31 | GBX16.67 Billion ≈ $2.03 Million |
GBX4.14 Billion ≈ $504.33K |
0.249x | +37.96% |
| 2015-12-31 | GBX18.44 Billion ≈ $2.24 Million |
GBX3.32 Billion ≈ $404.43K |
0.180x | -49.83% |
| 2014-12-31 | GBX19.65 Billion ≈ $2.39 Million |
GBX7.06 Billion ≈ $858.75K |
0.359x | +12.89% |
| 2013-12-31 | GBX23.25 Billion ≈ $2.83 Million |
GBX7.40 Billion ≈ $900.37K |
0.318x | +9.71% |
| 2012-12-31 | GBX23.95 Billion ≈ $2.91 Million |
GBX6.95 Billion ≈ $845.37K |
0.290x | -12.94% |
| 2011-12-31 | GBX23.47 Billion ≈ $2.86 Million |
GBX7.82 Billion ≈ $951.59K |
0.333x | -26.96% |
| 2010-12-31 | GBX23.41 Billion ≈ $2.85 Million |
GBX10.68 Billion ≈ $1.30 Million |
0.456x | -19.08% |
| 2009-12-31 | GBX20.82 Billion ≈ $2.53 Million |
GBX11.74 Billion ≈ $1.43 Million |
0.564x | +3.58% |
| 2008-12-31 | GBX16.06 Billion ≈ $1.95 Million |
GBX8.74 Billion ≈ $1.06 Million |
0.544x | +8.11% |
| 2007-12-31 | GBX14.91 Billion ≈ $1.81 Million |
GBX7.51 Billion ≈ $913.75K |
0.504x | +0.90% |
| 2006-12-31 | GBX15.42 Billion ≈ $1.88 Million |
GBX7.69 Billion ≈ $936.02K |
0.499x | +1.32% |
| 2005-12-31 | GBX13.69 Billion ≈ $1.67 Million |
GBX6.74 Billion ≈ $820.43K |
0.493x | +46.52% |
| 2004-12-31 | GBX14.50 Billion ≈ $1.76 Million |
GBX4.87 Billion ≈ $592.90K |
0.336x | +30.45% |
| 2003-12-31 | GBX13.26 Billion ≈ $1.61 Million |
GBX3.42 Billion ≈ $415.63K |
0.258x | -40.17% |
| 2002-12-31 | GBX11.22 Billion ≈ $1.37 Million |
GBX4.83 Billion ≈ $588.04K |
0.431x | +53.24% |
| 2001-12-31 | GBX9.63 Billion ≈ $1.17 Million |
GBX2.71 Billion ≈ $329.30K |
0.281x | +14.89% |
| 2000-12-31 | GBX9.55 Billion ≈ $1.16 Million |
GBX2.34 Billion ≈ $284.22K |
0.245x | +178.60% |
| 1999-12-31 | GBX10.35 Billion ≈ $1.26 Million |
GBX908.55 Million ≈ $110.54K |
0.088x | +9.62% |
| 1998-12-31 | GBX10.98 Billion ≈ $1.34 Million |
GBX879.74 Million ≈ $107.04K |
0.080x | -61.15% |
| 1997-12-31 | GBX3.62 Billion ≈ $440.89K |
GBX747.21 Million ≈ $90.91K |
0.206x | -4.16% |
| 1996-12-31 | GBX3.66 Billion ≈ $445.48K |
GBX787.75 Million ≈ $95.85K |
0.215x | +11.55% |
| 1995-12-31 | GBX3.04 Billion ≈ $369.44K |
GBX585.64 Million ≈ $71.25K |
0.193x | -15.95% |
| 1994-12-31 | GBX2.73 Billion ≈ $331.56K |
GBX625.36 Million ≈ $76.09K |
0.229x | -24.42% |
| 1993-12-31 | GBX2.32 Billion ≈ $282.74K |
GBX705.58 Million ≈ $85.85K |
0.304x | -75.00% |
| 1992-12-31 | GBX169.87 Million ≈ $20.67K |
GBX206.27 Million ≈ $25.10K |
1.214x | +120.37% |
| 1991-12-31 | GBX916.88 Million ≈ $111.56K |
GBX505.22 Million ≈ $61.47K |
0.551x | -53.33% |
| 1990-12-31 | GBX682.84 Million ≈ $83.08K |
GBX806.30 Million ≈ $98.10K |
1.181x | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more